Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease

Song MEI; Wen JIANG; Xiang-feng BAI; Wen-jie WANG; Dan HUANG; Wei CAO

doi:10.12259/j.issn.2095-610X.S20210121

Volume 42 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2021 > 42(1): 72-75

Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease[J]. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121

Citation:

Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease[J]. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121

Citation:

Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease[J]. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121

PDF( 599 KB)

Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease

doi: 10.12259/j.issn.2095-610X.S20210121

Dept. of Cardiovascular Surgery，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2020-08-22
Available Online: 2021-01-26
Publish Date: 2021-01-26

Abstract

Abstract

Objective To analyze the efficacy and safety of levosimendan in patients with heart failure caused by severe coronary heart disease. Methods From January 2018 to January 2020, 40 patients who were hospitalized with the diffuse coronary artery disease were selected and divided into two groups according to the selection of levosimendan or not, with 20 cases in each group. Cardiac function index, myocardial enzymes, BNP, liver and kidney function changes and adverse reactions of the two groups were collected and analyzed. Results After the corresponding treatment, it was found that changes in cardiac function were statistically significant（P < 0.05）and differences in myocardial enzymes and BNP were statistically significant（P < 0.05）between the two groups. Also, there was no significant difference in liver and kidney function（P > 0.05）and the incidence of adverse reactions was not statistically significant（P > 0.05）. Conclusion The effect of levosimendan on severe coronary heart disease is obvious and the side effects of the drug are small.
- Severe coronary heart disease,
- Levosimendan,
- Heart failure

FullText(HTML)

References(15)

References

[1]	Farooq V,van Klaveren D,Steyerberg E W,et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients:development and validation of SYNTAX score II[J]. The Lancet,2013,381(9867):639-650. doi: 10.1016/S0140-6736(13)60108-7
[2]	Revermann M,Schloss M,Mieth A,et al. Levosimendan attenuates pulmonary vascular remodeling[J]. Intensive Caremed,2011,37(8):1368-1377. doi: 10.1007/s00134-011-2254-9
[3]	Domaradzki W,Sanetra K,Krauze J,et al. Coronary endarterectomy in leftanterior descending artery combined with coronary artery bypass graftingmidterm mortality and morbidity[J]. Kardiochir Torakochirurgia Pol,2015,12(4):304-308.
[4]	Lv M Y,Deng S L,Long X F. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients:a meta-analysis[J]. Br J Clin Pharmacol,2016,81(1):174-185. doi: 10.1111/bcp.12788
[5]	杜贺,史承勇. 左西孟旦的研究新进展[J].中国循环杂志,2014,29(7):555-557. doi: 10.3969/j.issn.1000-3614.2014.07.020
[6]	徐芳,李铁成. 左西孟旦对老年冠状动脉旁路移植术患者生存及预后的影响[J].中国动脉硬化杂志,2019,27(12):1075-1079. doi: 10.3969/j.issn.1007-3949.2019.12.013
[7]	陈志刚. 左西孟旦对重症难治性心力衰竭患者血清脑利钠肽及尿酸水平的影响[J].临床合理用药杂志,2020,13(11):27-28.
[8]	Elin M Thorlacius,Håkan Wåhlander,Tiina Ojala,et al. Levosimendan versus milrinone for inotropic support in pediatric cardiac surgery:Results from a randomized trial[J]. Journal of Cardiothoracic and Vascular Anesthesia,2020,34(8):10-13.
[9]	张洪钦. 左西孟旦与多巴酚丁胺治疗急性失代偿性心力衰竭疗效和血液学指标比较[J].临床合理用药杂志,2020,13(8):3-4.
[10]	杨文清,陈涛. 左西孟旦治疗老年重度心力衰竭的疗效及安全性分析[J].中国农村卫生,2020,12(4):87-89. doi: 10.3969/j.issn.1674-361X.2020.04.087
[11]	陶硕秋,祁宏. 左西孟旦治疗射血分数减低慢性心衰患者的疗效及对心功能、炎症指标等的影响[J].心血管康复医学杂志,2020,29(1):68-72. doi: 10.3969/j.issn.1008-0074.2020.01.17
[12]	菲尔凯提·玉山江,穆叶赛·尼加提. 急性冠状动脉综合征合并急性心力衰竭的药物治疗进展[J].慢性病学杂志,2020,21(1):49-51.
[13]	张美兰. 左西孟旦治疗老年重度心力衰竭的疗效及安全性分析[J].中西医结合心血管病电子杂志,2019,7(35):55-58.
[14]	冯婧,鲁佳佳,赵琳. 重组人脑利钠肽联合左西孟旦对老年急性失代偿性心力衰竭患者心功能和血清N末端B型脑钠肽前体及和肽素水平的影响[J].中国医药,2020,15(5):665-668.
[15]	陈志平. 左西孟旦联合缬沙坦治疗老年重症心力衰竭的疗效及不良反应率观察[J].心血管病防治知识(学术版),2019,9(22):29-31.

Relative Articles(20)

Relative Articles

[1]	Yan QIU, Yinli WANG, Mengmeng YANG, Liangmin GUO, Longhui YUAN. Association between MPV，PDW，PCT and Cardiac Function in Patients with Pulmonary Hypertension. Journal of Kunming Medical University, 2023, 44(12): 121-126. doi: 10.12259/j.issn.2095-610X.S20231219
[2]	Mei YANG, Ping WANG, Hui YANG, Gonghao HE. Potential Therapeutic Targets and Research Progress of Related Drugs of Heart Failure. Journal of Kunming Medical University, 2023, 44(7): 156-161. doi: 10.12259/j.issn.2095-610X.S20230719
[3]	Wei-jie SU, Mei-sha ZHANG, Jia-ning LI, Ying LIU, Ding-jie XU, Hong CHANG. Establishment of Rat Myoblast Atrophy Model Induced by Ang Ⅱ. Journal of Kunming Medical University, 2021, 42(10): 8-13. doi: 10.12259/j.issn.2095-610X.S20211026
[4]	Li Jie , Zhang Shi Ming , Yang Shu Lian . . Journal of Kunming Medical University, 2020, 41(01): 31-36.
[5]	Zhang Ti Ling , Zhang Wei Hua , Luo Qing 祎, Xia Hong Ying , Lu Yi Bing . . Journal of Kunming Medical University, 2020, 41(03): 91-95.
[6]	Jian-pei SU, Wei-meng TIAN, Jun GU, Mi-yu HE. Association between C-reactive Protein/Albumin Ratio and Long-term Prognosis in Elderly Patients with Heart Failure. Journal of Kunming Medical University, 2020, 41(12): 128-132. doi: 10.12259/j.issn.2095-610X.S20201236
[7]	Zhu Guo Fu , Quan Qiang , Wu Li Yong , Ruan Zhi Min , Zhang Ming Guo , Chu Tian Shu . . Journal of Kunming Medical University, 2019, 40(07): 56-61.
[8]	Zou Hong Lin , Jia Zheng , Xing Zheng Jiang , Li Ya Xiong , Wei Jie , Sun Xiao Lin , Meng Fan Di , Liu Fei Fei . . Journal of Kunming Medical University, 2019, 40(09): 62-67.
[9]	Wang Xu , Deng Hong , Li Ming Zhou , Xing Xi Qian . . Journal of Kunming Medical University, 2018, 39(09): 87-90.
[10]	Shi Ye , Niu Xiao Qun , Cao Yu , Li Hui . . Journal of Kunming Medical University, 2017, 38(02): 78-81.
[11]	Ye Xue Qun , Nie Lei . . Journal of Kunming Medical University, 2017, 38(02): 95-98.
[12]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[13]	Li Yan Ping . The Clinical Characteristics of Patients with Chronic Heart Failure with Preserved Ejection Fraction. Journal of Kunming Medical University,
[14]	Yuan Hua Yuan . . Journal of Kunming Medical University,
[15]	Zhang Ji Lei . . Journal of Kunming Medical University,
[16]	Chen Qiu . . Journal of Kunming Medical University,
[17]	Ding Cheng Yan . . Journal of Kunming Medical University,
[18]	Dai Hai Long . . Journal of Kunming Medical University,
[19]	Chang Song Jie . . Journal of Kunming Medical University,
[20]	. Clinical Analysis of 59 Old Chronic Heart Failure Patients Complicated with Hyponatremia. Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(14)

1.	陈涛，谢云志. 左西孟旦联合多巴酚丁胺治疗老年急性心肌梗死合并心源性休克的效果. 中国药物滥用防治杂志. 2024(03): 504-507 .
2.	刘晓晨，苏国宝，周朝元，王俊华. 左西孟旦联合心脉隆对冠心病心力衰竭患者血清VEGF、TGF-β、NT-pro BNP检测的分析. 实验与检验医学. 2024(01): 109-112 .
3.	郑生，孟令东. 间断重复应用左西孟旦治疗肺动脉高压合并严重右心衰竭患者的临床效果分析. 青海医药杂志. 2024(05): 9-12 .
4.	武琼，涂胜，董松武，江荣炎. 左西孟旦治疗冠心病心功能不全患者的疗效及对生活质量的影响分析. 中国循证心血管医学杂志. 2023(03): 319-321+328 .
5.	于晓东，任晓艺，刘美霞. 左西孟旦应用于机体重要器官疾病的研究进展. 临床荟萃. 2023(06): 573-576 .
6.	王瑜. 左西孟旦治疗心力衰竭的临床疗效及其对患者心功能及炎性反应的影响. 临床合理用药杂志. 2022(21): 8-10+14 .
7.	李雅丽，刘亚丽. 基于左心室功能、血清细胞因子水平变化评价左西孟旦在老年急性心肌梗死患者经皮冠状动脉介入术后心力衰竭治疗中的应用. 中国临床医生杂志. 2022(11): 1315-1319 .
8.	张宪明，王智彬，杨迅. 左西孟旦对冠心病合并心力衰竭患者心室重构及血清hs-CRP、IGF-1水平的影响. 临床医学工程. 2022(12): 1665-1666 .
9.	刘永平，王华亭. 分析左西孟旦治疗重症冠心病并心力衰竭对心肌酶、不良反应及炎症因子的研究. 中外医疗. 2022(32): 41-44 .
10.	何潇. 不同剂量左西孟旦治疗老年重症心力衰竭的临床研究. 中国现代医学杂志. 2021(10): 24-28 .
11.	李俊梅，李荣荣，陈晓娟，胡晓雷，米丹丽，李建英. CBP协同左西孟旦联合伊伐布雷定治疗重症肺炎合并心力衰竭患者疗效观察及对MIP-2、IgG水平的影响. 临床和实验医学杂志. 2021(14): 1485-1489 .
12.	王紫监，程光慧，张海洋，陈敏，许晓伟，苏维芳，李新军. 左西孟旦治疗经皮冠状动脉介入术后无复流心力衰竭患者疗效. 中国临床医生杂志. 2021(12): 1425-1427 .
13.	徐健，周雪，赵纯，李秀玲. 左西孟旦联合芪苈强心胶囊对顽固性心力衰竭的疗效分析. 中外医疗. 2021(32): 95-97+101 .
14.	石红霞. 左西孟旦对重症冠心病合并心力衰竭患者的治疗效果. 名医. 2021(21): 151-152 .